P1 Bacteriophage-Enabled Delivery of CRISPR-Cas9 Antimicrobial Activity Against *Shigella flexneri*

Yang W. Huan, Vincenzo Torraca, Russell Brown, Jidapha Fa-arun, Sydney L. Miles, Diego A. Oyarzún, Serge Mostowy,* and Baojun Wang*

**ABSTRACT:** The discovery of clustered, regularly interspaced, short palindromic repeats (CRISPR) and the Cas9 RNA-guided nuclease provides unprecedented opportunities to selectively kill specific populations or species of bacteria. However, the use of CRISPR-Cas9 to clear bacterial infections in vivo is hampered by the inefficient delivery of cas9 genetic constructs into bacterial cells. Here, we use a broad-host-range P1-derived phagemid to deliver the CRISPR-Cas9 chromosomal-targeting system into *Escherichia coli* and the dysentery-causing *Shigella flexneri* to achieve DNA sequence-specific killing of targeted bacterial cells. We show that genetic modification of the helper P1 phage DNA packaging site (pac) significantly enhances the purity of packaged phagemid and improves the Cas9-mediated killing of *S. flexneri* cells. We further demonstrate that P1 phage particles can deliver chromosomal-targeting cas9 phagemids into *S. flexneri* in vivo using a zebrafish larvae infection model, where they significantly reduce the bacterial load and promote host survival. Our study highlights the potential of combining P1 bacteriophage-based delivery with the CRISPR chromosomal-targeting system to achieve DNA sequence-specific cell lethality and efficient clearance of bacterial infection.

**KEYWORDS:** *Shigella flexneri*, P1 bacteriophage, CRISPR-Cas9, antimicrobial, phagemid

**INTRODUCTION**

CRISPR (clustered, regularly interspaced, short palindromic repeats), in combination with the Cas (CRISPR-associated) endonuclease enzyme(s), constitutes the immune system of prokaryotes, serving to protect bacteria against invading nucleic acids. Cas9 is an RNA-guided endonuclease that introduces double-strand cleavage at its target DNA sequence, while the specificity is determined by the spacer sequence of CRISPR RNA (crRNA), which is complementary to the target DNA sequence. Previous studies demonstrated that the CRISPR-Cas9 system can be programmed to target antibiotic-resistance gene(s) or species-specific chromosomal gene(s) of bacteria. Such targeting can re-sensitize bacterial populations to antibiotic treatment or, in the latter case, induce cell lethality via SOS-mediated responses against double-stranded DNA damage in the bacterial chromosome. Cell lethality via DNA sequence-specific targeting has been described for various clinically relevant bacterial pathogens, such as antimicrobial-resistant strains of *Escherichia coli*, *Staphylococcus aureus,* and *Salmonella enterica* spp. Despite this success, the use of CRISPR-Cas9 as an antimicrobial system is hampered by the low transformation efficiency of target bacteria, especially during infections in vivo.

Bacteriophages, viruses that predate bacterial cells, have been used to treat bacterial infections for over a century. New strains of lytic bacteriophages recovered from environmental and biological samples are routinely used in studies to kill clinically relevant and/or multidrug-resistant strains of bacteria, including *Clostridium difficile*, *Shigella flexneri*, *Pseudomonas aeruginosa*, and methicillin-resistant *S. aureus* (MRSA). Although the direct use of lytic bacteriophage cocktails is not widely accepted as a reliable alternative to antibiotics in the clinical field, properties of bacteriophages such as their specific host range, high transduction efficiency, stability of bacteriophage particles, and the ability of certain bacteriophages to lysogenize into host cells make them suitable as an efficient delivery tool for genetic constructs. Citorik *et al.* demonstrated M13 phagemid-based delivery of the Cas9 system into carbapenem-resistant *E. coli* to target its antibiotic resistance determinants *blaNDM-1* or *blaSHV-12* which allowed re-sensitization of the bacteria toward antibiotic treatment in *vitro*. In addition, the Cas9 endonuclease was reprogrammed to target a chromosomally encoded virulence factor (*eae*) of...
enterohemorrhagic *E. coli*, which allowed DNA sequence-specific killing of the bacteria in a *Galleria mellonella* infection model.\(^\text{17}\) Bikard *et al.* demonstrated the use of the ΦNM1 bacteriophage to deliver phagemid-encoded CRISPR Cas9 antimicrobial systems into *S. aureus*.\(^\text{18}\) In this case, reprogramming of the Cas9 endonuclease to target the methicillin resistance gene, mecA, was introduced to specifically kill the methicillin-resistant strain USA300Φ but not the RNΦ strain *in vitro*. The sequence-specific killing effect of Cas9 was expanded to target the chromosomal *aph* gene of the RNKΦ strain, which selectively reduced 40% of the RNKΦ cells *in vivo* using a mouse skin colonization model.\(^\text{19}\) Recently, the M13 phagemid-based delivery of the Cas9 system allowed the selective killing of a F\(^+\) *E. coli* strain in a murine gut colonization model.\(^\text{20}\) In this case, the authors demonstrated a selective reduction of a *gfp* F\(^+\) *E. coli* strain (approximately 1–3 log), using a *gfp*-targeting M13 cas9 phagemid.\(^\text{21}\) Taken together, these studies have suggested that bacteriophages allow efficient delivery of DNA sequence-specific Cas9 antimicrobials into bacteria *in vivo* and strongly support the approach as an alternative therapeutic option to treat bacterial infections.

Shigellosis is an acute intestinal infection caused by *Shigella* spp. Worldwide, it was estimated that *Shigella* caused 80–165 million cases of disease and 600,000 deaths annually.\(^\text{19}\) *S. flexneri* is most frequently recorded in developing countries, with a disproportionately high mortality rate in children.\(^\text{20–22}\) Clinical isolates of *S. flexneri* are often drug resistant, and it was estimated that half of all contemporary strains of *Shigella* spp. are multidrug resistant.\(^\text{23}\) This calls for alternative therapeutic options, such as the use of bacteriophages in treating *Shigella* infection. In this study, we demonstrate the use of a broad-host-range transducing P1 phagemid system to deliver chromosomal-targeting cas9 genetic constructs into *E. coli* and the dysentery-causing *S. flexneri* to achieve sequence-specific lethality of targeted bacterial cells. To reduce the packaging of the resident P1 bacteriophage genome, we performed genetic modification of the *pac* site, the recognition site for the pacase enzyme, to bias the packaging of *cas9* phagemid into P1 phage particles. We show that an improved titer of P1 transducing units in the lysates prepared from *pacA*\(^\text{-}::\text{npt}\) EMG16 cells significantly enhanced the Cas9-mediated lethality effect on *S. flexneri*. Moreover, we show that the *cas9* chromosomal-targeting phagemid is efficient in inducing sequence-specific lethality of *S. flexneri* *in vivo* and significantly improved the survival of infected zebrafish larvae. Overall, these results highlight the potential of P1-based phagemid delivery of the chromosomal-targeting CRISPR-Cas9 system as a powerful tool to target clinically relevant and antibiotic-resistant Gram-negative *Enterobacteriaceae* pathogens.

## RESULTS

### Construction of P1 BBa_J72114 Phagemid with High Transduction Efficiency in *E. coli* Strains.

To deliver and stably express foreign genetic cassette(s) in *Enterobacteriaceae*, the BBa_J72114 P1 phagemid constructed for this study contains all necessary P1-based elements for packaging of phagemids into P1 bacteriophage particles (refer to Supporting Information Figure S1 for details), as well as a selectable chloramphenicol-resistance marker and p15A or pBBR1 origin of replication for phagemid maintenance (Figure 1a).

**Figure 1.** P1 J72114 phagemid as a delivery tool for transduction of a foreign genetic cassette into Gram-negative *Enterobacteriaceae*. (a) Schematic diagram of P1-J72114 phagemid, characterized by constitutive expression of *gfp* placed under the BBa_J23115 promoter. The phagemid contains the chloramphenicol acetyltransferase gene (*cat*), which confers a chloramphenicol-resistant phenotype to transduced or transformed cells. Transduced *E. coli* cells will retain the J72114-*gfp* phagemid, giving constitutive *gfp* expression. (b) Representative image showing the presence of GFP-positive *E. coli* NCM3722 cells after transduction with serially diluted phage lysates delivering the *gfp* expression cassette. Serial dilutions of recovered cells (10\(^{-5}\), 10\(^{-6}\), and 10\(^{-7}\)) were made and spotted onto LB agar supplemented with chloramphenicol. (c) Quantitation of transducing units (phage particles containing phagemid sequences) in various lab strains of *E. coli*. Each data point represents a biological replicate and is the average of four technical repeats. Horizontal lines represent the group mean. The *p*-values were determined and adjusted by the Kruskal–Wallis test and Dunn’s multiple comparison tests, respectively, and significance was defined as *p* < 0.05. * represents *p* < 0.05, while ** represents *p* < 0.005, for comparisons between BL21 vs NCM3722 and TOP10 vs MC1061 and phagemid transductants, respectively.

Due to the non-replicative nature of the P1 phagemid, we hypothesized that a multiplicity of infection (MOI) greater than or equal to 1 might be required for efficient transduction of the phagemid.\(^\text{5,7}\) To quantify the P1 transducing units’ titer of lysates prepared, the original phagemid was modified to include a constitutive *gfp* expression cassette (J72114-*gfp*, Figure 1a). Various lab strains of *E. coli* were transduced with P1 phage lysates, and recovered cells were selected for chloramphenicol resistance and GFP fluorescence (Figure 1b). The P1 lysates transduced all three substrains of *E. coli* K-12 and *E. coli* BL21 within a range of 7 × 10\(^8\) to 7 × 10\(^9\) transducing units per millilitre of lysate used (Figure 1c). Overall, our protocol generates sufficient phagemid titters for the delivery and stable expression of genetic constructs in *E. coli*.

### Efficacy of Cas9-Induced Cell Lethality of *E. coli* MC1061::*npt*.

We constructed two J72114-*cas9* phagemids to achieve sequence-specific DNA cleavage on target enterobacterial cells. The complete Cas9 system was derived from the pCas9 plasmid with constitutive expression of *cas9*, trans-activating RNA (*tracRNA*), and CRISPR RNA (*crRNA*) (Figure 2a). The specificity and efficacy of Cas9 endonuclease-mediated lethality were first evaluated on the *E. coli* K12 strain MC1061::*npt*, which has a single copy of the chromosomally integrated *npt* gene conferring kanamycin

https://doi.org/10.1021/acssynbio.2c00465

ACS Synth. Biol. XXX, XXX, XXX–XXX
resistance. The npt-targeting spacer sequence was cloned into cas9 phagemid using a BsaI cloning system (refer to Supporting Information Table S3 for DNA sequences). Since E. coli MC1061::npt is not a recombination-deficient mutant, chromosomal DNA double-strand breaks (DSBs) caused by Cas9 endonuclease(s) in the presence of chromosomal-targeting spacer sequence(s) would induce an SOS-mediated chromosomal DNA double-strand breaks (DSBs) caused by E. coli cas9 phagemid using a BsaI cloning system (refer to Supporting Information Figure S2). This verified that the specificity of Cas9-mediated lethality depends on the presence of both the npt-targeting spacer sequence and the chromosomal npt gene sequence.

Overall, these results show that the cas9 phagemid with the chromosomal-targeting spacer sequence is unstable or conditionally lethal when introduced into target bacterial cells.

**Genetic Modification of the pac Site of the P1 Genome to Improve P1 Phagemid Purity.** Previous results showed that P1 phagemid lysates confer general cytotoxicity on E. coli K12 MC1061 cells, irrespective of the presence or absence of the Cas9 spacer sequence. The nonspace sequence-mediated lethality effect (termed general cytotoxicity of lysate) may be attributed to the presence of wildtype P1 phage in the lysates, which are capable of undergoing lytic-stage replication, hence the killing of transduced cells. This prompted us to genetically remove the DNA packaging site, pac, on the resident wildtype P1 phage to bias the packaging of cas9 phagemid and reduce wildtype P1 phage titer. The 161 bp pac sites lie within the pacA gene sequence and contain seven hexameric repeats (“TGATCA/G”) with the “GATC” Dam
methylation site.\textsuperscript{34,35} Previous studies proposed that the hemimethylated pac site would be recognized and bound by the pacase enzyme, while further methylation would promote cleavage of the pac site by the bound pacase.\textsuperscript{34–36} We hypothesized that disruption of these hexamer repeat motifs would reduce the packaging of the wildtype P1 genome. The \textit{E. coli} P1 lysogen EMG16 strain with a modified pacA gene sequence (termed \textit{pacA*::npt}) was created by introducing synonymous mutations into the hexamer repeats of the pac site via lambda-red recombineering (Figure 3a,b). Phage lysates of the \textit{cas9} phagemid without chromosomal-targeting spacer sequences were prepared from wildtype and \textit{pacA*::npt} EMG16 cells. Quantification of plaque-forming units and transducing units suggested that lysates prepared from the \textit{pacA*::npt} mutant contained approximately 9-fold lower wildtype P1 phage titer compared to that of lysates prepared from wildtype EMG16 cells ($p < 0.0005$, Figure 3c). There was no significant difference in the phagmid titers of lysates prepared from both wildtype and \textit{pacA*::npt} EMG16 cells, indicating that the \textit{pacA} genetic modification had negligible effects on the packaging of phagemid into transducing units ($p > 0.05$, Figure 3c).

Overall, these results highlight an improvement in phagemid purity, with a significantly reduced ratio of wildtype P1 phage to phagemid for lysates prepared from the \textit{pacA*::npt} EMG16 mutant cell line ($p < 0.0005$, Figure 3d).

\textbf{Efficiency of \textit{cas9} Phagemid-induced Cell Lethality of \textit{S. flexneri}.} Results obtained so far support our hypothesis that the presence of a spacer sequence complementary to an \textit{E. coli} chromosomal gene can lead to cell lethality via its \textit{Cas9} endonuclease activity. We next chose to test the delivery and properties of the J72114-\textit{cas9} phagemid constructs in the context of \textit{S. flexneri}, the causative agent of shigellosis (also called bacillary dysentery), with high rates of mortality and morbidity among children aged under 5 years in developing countries.\textsuperscript{21} Spacer sequence-mediated lethality effect of the \textit{cas9} phagemid on \textit{S. flexneri} was first tested using \textit{cas9} phagemids with spacer sequences designed to target four conserved virulence (and chromosomal) genes of \textit{S. flexneri}: \textit{sigA}, \textit{pic}, \textit{shiD}, and \textit{shiA} (refer to Supporting Information Table S4 for spacer sequences).\textsuperscript{37–40} To optimize the delivery of the \textit{cas9} phagemid to a new host, a broad-host-range origin of replication, \textit{pBBR1}, was chosen for the J72114-\textit{cas9} phagemid (Figure 4a). To validate the targeting efficiencies of the spacer sequences designed, we treated an atrivan strain of \textit{S. flexneri} (strain 2a 24570) using crude P1 \textit{cas9} phagemid lysates prepared from wildtype \textit{E. coli} P1 lysogen. These results showed that spacer sequence(s) targeting the \textit{sigA}, \textit{pic}, \textit{shiD}, and \textit{shiA} genes reduced the number of \textit{S. flexneri} CFU, by ∼5-fold ($p < 0.05$), ∼16-fold ($p < 0.05$), ∼72-fold ($p < 0.0005$), and ∼75-fold ($p < 0.0005$), respectively, when compared to \textit{cas9}-NT phagemid treatment ($p$-values determined with the Kruskal–Wallis test and adjusted with Dunn’s multiple comparison test) (Figure 4b). Since the targeted virulence genes are not linked to the survival of \textit{S. flexneri} cells in \textit{vitro}, the conditional lethality observed is likely to be due to DSB cleavage on the chromosome by the \textit{Cas9} endonuclease. These results indicate the functionality of the four spacer sequences in specific targeting of \textit{S. flexneri} chromosomal genes for \textit{Cas9}-mediated disruption and cell lethality.

We next sought to validate the chromosomal-targeting efficiency of our \textit{cas9}-\textit{shiA} phagemid on a pathogenic strain of \textit{S. flexneri} M90T serotype 5a, which is widely used as a paradigm for cellular microbiology studies and \textit{in vivo} invasion assays.\textsuperscript{34,35} The \textit{cas9}-\textit{shiA} phagemid was chosen for further transduction assays because it gave the highest spacer sequence-mediated lethality on \textit{S. flexneri} 2a 24570. P1 lysates of the \textit{cas9}-\textit{shiA} phagemid, as well as its respective non-

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Figure3.png}
\caption{Genetic modification of the pac site, within the pacA coding sequence of the wildtype P1 bacteriophage genome to reduce wildtype P1 phage DNA packaging. (a) Schematic diagram showing the minimal pac sequence of the P1 phage genome, situated within the pacA coding sequence. Methylation sites, consisting of hexameric repeats, HEX4 and HEX3, are shown in black, the IHF binding site is shown in green, and the pac cleavage site is shown in orange. Synonymous mutations were introduced onto the hexameric repeats to disrupt the binding of PacA and PacB. A Comparison with the wildtype pac DNA sequence is shown, with mutated DNA bases indicated in red. (b) Schematic diagram showing the processing of the pac site, involving the binding of PacA and PacB to the hexameric repeats, as well as IHF and HU binding, which was proposed to give a bent structure of the pac site. Pacase (both PacA and PacB) enzymatic activity then leads to cleavage of the pac site. (c) Summary of pacase (both PacA and PacB) enzymatic properties of the J72114-\textit{cas9} phagemid without spacer sequence(s) targeting the \textit{cas9} phagemid on a pathogenic strain of \textit{S. flexneri} EMG16 cells harboring J72114-\textit{cas9}-NT phagemid without spacer sequence(s) targeting \textit{E. coli} or \textit{S. flexneri} chromosomal sequences. (d) Ratio of wildtype P1 phage to P1 transducing units was calculated and plotted. Each data point represents a biological replicate and is the average of four technical repeats. Horizontal bars represent the group mean. The *-values (between wildtype and pacA*::npt lysates) were determined using a two-tailed unpaired $t$-test with significance defined by $p < 0.05$. $p < 0.0005$ between the P1 phage titer of lysates prepared from wildtype and pacA*::EMG16 lysogen, as well as the PFU/TU ratio between lysates prepared from wildtype and pacA*::EMG16 lysogen are shown as ***.}
\end{figure}
from pacA*::npt EMG16 cells, treated with PEG-6000, and used for transduction assays on S. flexneri. To identify the optimal dosage, a range of MOIs (2.0, 4.0, 6.0, 8.0, and 10.0) was used for the transduction assay. These results showed that an MOI value > 2.0 gave the highest spacer sequence-mediated killing effect on S. flexneri cells, causing a $3.8 \times 10^3$ to $5.1 \times 10^3$ reduction in S. flexneri CFU ($p < 0.0005$) after treatment with cas9-shiA phagemid (Figure 4c).

The non-Cas9-mediated killing effect at MOIs of 2.0 to 4.0 reduced S. flexneri CFU by approximately 3.1-fold ($p > 0.05$) and 6.7-fold ($p > 0.05$), respectively, when compared to an input of $1 \times 10^7$ S. flexneri CFU (p-values determined with the Kruskal–Wallis test and adjusted with Dunn’s multiple comparison test). We determined that an MOI value of ~4.0 is optimal, considering that a further increase in MOI would lead to an increase in the non-spacer sequence-mediated lethality effect of lysates without significant changes to the

Figure 4. Cas9-mediated lethality of S. flexneri using chromosomal-targeting J72114 cas9-shiA phagemid. (a) Schematic diagram showing the cas9 genetic construct of P1 J72114 phagemid, with spacer sequence targeting chromosomal gene(s) (i.e., shiA) of S. flexneri (in green). Upon transduction, the presence of crRNA with a spacer sequence complementary to the chromosomal genes of S. flexneri (ct-crRNA) would cause dsDNA cleavage of the chromosome via Cas9 endonuclease, leading to cell death. (b) J72114 cas9 phagemid with spacer sequence(s) targeting the sigA, pic, shiD, and shiA chromosomal genes of S. flexneri 2a 2457O. Lysates were prepared from the wildtype EMG16 cell line. Crude lysates were used for transduction of S. flexneri 2a 2457O, with a MOI of 10 wildtype P1 phages (equivalent to 5 transducing units) to 1 bacterial cell. Data were plotted as change(s) in CFU as compared to input CFU (approximately 1 $\times 10^7$ cells per reaction) used for infection. (c) Spacer sequence-mediated lethality of S. flexneri 5a MT905 cells with chromosomal-targeting cas9-shiA (in orange) and nontargeting cas9-NT phagemids (in blue) in lysates prepared from the pacA*::npt EMG16 cell line. MOIs of 2.0, 4.0, 6.0, 8.0, and 10.0 were used. Data were plotted as changes in CFU as compared to input CFU (approximately 1 $\times 10^7$ cells per reaction) used for infection. The number of CFU recovered from the mock infection was shown in black. (d) Cas9 spacer sequence-mediated lethality effect of cas9-shiA phagemid and (e) Nonspacer sequence-mediated lethality effect of cas9 phagemid lysate prepared from wildtype (WT, in black) and pacA*::npt EMG (in orange) cell lines. MOIs of 2, 4, 6, 8, and 10 P1 transducing units to 1 bacterial cell for pacA*::npt EMG lysates were used. For wildtype EMG16 lysates, MOIs of 2.0, 4.0, 6.0, 8.0, and 10.0 wildtype P1 phages per bacterial cell were used, and the wildtype P1 phage to P1 transducing units is approximately 2 for lysates prepared from the wildtype EMG16 cell line. The cas9-shiA-mediated lethality effect was quantified by measuring the reduction in CFU recovered after treatment with cas9-shiA and cas9-NT phagemids. Mock infections involved treating S. flexneri cells with SM buffer. The reduction in CFU recovered between cas9-NT phagemid treatment and the input cells used for infection (approximately 1 $\times 10^7$ cells per reaction) would show the nonspacer sequence-mediated lethality effect of P1 phage lysates at all four MOIs tested. Each data point represents a biological repeat and is the average of four technical repeats. Horizontal bars represent the group mean.
Cas9-mediated lethality effect (Figure 4c). We did not recover any chloramphenicol-resistant S. flexneri CFU after treatment with cas9-shiA phagemid, thus validating the efficiency of its spacer sequence-mediated cell lethality.

To improve the effect of the pacA*::npt mutation on improving the quality of lysate, results were compared to those of lysates prepared from wildtype EMG16 cells. Lysates prepared from wildtype EMG16 cells required an MOI of approximately 60 for a maximum Cas9-mediated lethality effect of ~100-fold reduction in CFU (Figure 4d), which was accompanied by a non-spacer sequence-mediated killing effect of approximately 40-fold reduction in CFU (Figure 4e). In contrast, the maximum Cas9-mediated lethality effect of pacA*::npt lysates was observed at a MOI of ~4, producing a ~16-fold higher DNA sequence-specific killing effect ($p < 0.05$) and a ~12-fold lower non-Cas9-mediated killing effect ($p < 0.05$), when compared to that of lysates prepared from wildtype P1 lysogen at a MOI of 6 ($p$-values determined with the Kruskal–Wallis test and adjusted with Dunn’s multiple comparison test) (Figure 4d,e).

These results demonstrate the specificity and efficiency of our cas9-shiA phagemid in killing S. flexneri 5a M90T cells in vitro. We concluded that pacA*::npt lysates could achieve their maximum Cas9-mediated lethality effect at a lower MOI as compared to lysates prepared from wildtype EMG16 cells, hence giving a lower non-spacer sequence killing effect of phagemid lysates on S. flexneri cells.

Validating the Efficiency of the P1 cas9 Phagemid System In Vivo to Control Lethal S. flexneri Infection in Zebrafish Larvae. We next sought to establish whether our P1 cas9 phagemid system could clear S. flexneri infection in vivo. A variety of studies have shown that zebrafish larvae are susceptible to S. flexneri infection, with key aspects of the human disease being replicated in this model.²¹–²³ Zebrafish larvae are recognized as highly versatile for studying innovative treatments against S. flexneri infection.²⁴,²⁵ For example, clearance of drug-resistant S. flexneri infection in vivo has been achieved via the injection of the predatory bacteria Bdellovibrio bacteriovorus.²⁶ To assess the spacer sequence-mediated killing effect of our P1 cas9 phagemid, P1 phage lysates of cas9-shiA and cas9-NT phagemid (without chromosomal-targeting spacer sequence) were injected into the hindbrain ventricle of zebrafish larvae at 2 days post-fertilization, following the administration of a lethal dose (~8000 CFU) of S. flexneri 5a M90T. We observed an approximately tenfold reduction in S. flexneri CFU after treatment with cas9-shiA phagemid at 6 h post-infection (hpi), compared to that of nontargeting cas9-NT phagemid treatment ($p < 0.005$, Figure 5a). This was accompanied by a ~20% increase in the survival rate of zebrafish larvae ($p < 0.005$) (Figure 5b). In contrast, there were no significant differences in the number of S. flexneri CFU recovered at 6 hpi or the survival rate of zebrafish larvae at 24, 48, and 72 hpi between cas9-NT phagemid treatment and mock infections ($p > 0.05$) (Figure 5c).
(Supporting Information Figure S3a,b). Injection with either the cas9-shiA or cas9-NT phagemid alone without S. flexneri infection did not lead to morphological defects or reduced viability of zebrafish larvae (Supporting Information Figure S4). Overall, these results demonstrate the efficiency of cas9-shiA chromosomal-targeting phagemid in reducing S. flexneri bacterial load in vivo and improving the survival of the infected host (Figure 5c). Considering the nonreplicative nature of the P1 phagemid, our results highlight the potential use of cas9 phagemids as a safe and efficient therapeutic agent in vivo.

**DISCUSSION**

In this study, we demonstrate P1 phagemid-based delivery of a chromosomal-targeting cas9 genetic construct into E. coli and S. flexneri cells. We establish protocols that give a high phagemid titer and introduce the use of pacA::npt EMG16 cell line, which gives improved phagemid purity of lysates. We show efficient killing of S. flexneri cells with cas9 phagemid in the presence of spacer sequences complementary to the chromosomal gene(s) of S. flexneri. Finally, treatment of S. flexneri-infected zebrafish larvae with chromosomal-targeting cas9-shiA phagemid significantly reduced the bacterial burden and improved host survival.

We chose the P1 bacteriophage to deliver our phagemids into E. coli and S. flexneri due to its (1) ability to package large-sized DNA (~100 kbp), (2) high transduction efficiency among Gram-negative Enterobacteriaceae, (3) ability to lysogenize after transduction, and (4) in trans induction of single gene expression, coi, which can promote lytic stage replication. Using the P1-phagemid system with arabinose-inducible coi gene expression, our results are consistent with observations from previous studies, showing a transduction efficiency of at least 7 × 10⁶ transducing units per mL lysate used on E. coli. We observed a significantly lower transduction efficiency of the P1 phagemid for the E. coli TOP10 cell, and such reduced transduction efficiency had previously been reported on several recA-strains of E. coli. Previous studies suggested that only a subset of P1 phage particles contain Cre recombinase, while the rest of the P1 phage DNA relies on the host cells' homologous recombination system, such as RecA- and RecBCD-mediated homologous recombination of Chi sites, for the circularization of linear genomic DNA. Chi sites are over-represented in the genome of the P1 bacteriophage, and the cin gene sequence contains 2 of the 50 identified Chi sites, which may have improved the transduction efficiency of our P1 phagemid.

Our results demonstrate that the P1 phagemid is efficient in delivering the cas9 genetic constructs into both E. coli and S. flexneri. We show that the presence of spacer sequences complementary to the targeted chromosomal gene(s) of E. coli and S. flexneri yielded a 2 to 3 log reduction in bacterial CFU in vitro, which is comparable with the Cas9-chromosomal-targeting effect reported in previous studies. The efficiency of the cas9-shiA-targeting phagemid in reducing S. flexneri bacterial load in vivo was demonstrated as early as 6 hpi, with an approximately tenfold reduction in CFU, thus leading to a ~20% increase in the survival rate of infected larvae. The reduced shiA-targeting spacer sequence-mediated lethality effect, when compared to phagemid treatment in vitro, may be due to differences in experimental conditions (i.e., temperature, duration of infection, and environmental conditions), the lifecycle of S. flexneri infection in vivo, and/or a lower rate of phagemid transduction. In agreement, we did not observe a significant non-Cas9-mediated killing effect of the P1 cas9 phagemid in zebrafish larvae (when compared to mock infections), so the data suggest a lower rate of phagemid transduction as compared to in vitro assays. Our current lysates contain a maximum of ~4 × 10⁷ to ~8 × 10⁷ phagemid-transducing particles (per mL sample), which might have limited the rate of phage infection in vitro. Furthermore, we hypothesize that the P1 bacteriophage is unable to cross the host epithelial cell membrane efficiently, and thus, the primary target cells of the phagemid might be restricted to the extracellular pool of S. flexneri, while intracellular bacteria could proliferate and kill the host. Previous studies showed that repeated administration of phages enhanced clearance of bacterial infections in vivo, which might improve the performance of our cas9 phagemid. However, we did not distinguish whether the surviving S. flexneri colonies recovered after shiA-targeting phagemid lysate treatment were P1-resistant colonies and/or escape mutants of the Cas9 chromosomal-targeting effect. If the surviving S. flexneri are resistant to P1 infection, repeated administration of phagemid lysates may not improve the overall Cas9-mediated killing of bacteria. The factor(s) which may be associated with resistance against phage infection and/or the Cas9 chromosomal-targeting system could be identified by genomic sequencing of surviving S. flexneri colonies. These data could provide insights into ways of improving our current P1 phagemid system, such as the engineering of P1 tail fiber to overcome phage resistance, the use of multiple chromosomal-targeting guide RNAs, and/or the use of other RNA-guided endonucleases to enhance the antimicrobial effect. In addition, our study lacks pharmacokinetic analysis to investigate the interactions between P1 phage and the host immune response, which could dictate the efficiency of our P1 phage-based delivery method. Future assessment of the interactions between P1 phage and the host immune system, as well as the concentration of phagemid transducing particles and treatment at higher MOIs, might provide solutions to enhance the stability of P1 phage and rate of phage transduction, which could improve clearance of infection in vivo.

Given the nonreplicative nature of the P1 cas9 phagemid, a higher MOI is required for a significant spacer sequence-mediated lethality effect. However, our results showed that an increase in MOI would also lead to an increase in the general cytotoxicity effect of phagemid lysates on E. coli and S. flexneri. We demonstrated that this could be mitigated via PEG-6000 treatment of lysates and the genetic modification of the pac site on the P1 genome by reducing the recovery of wildtype P1 phage and its DNA packaging, respectively. The improved phagemid purity allowed for higher spacer-specific lethality at a lower MOI. It is noteworthy that transduction of a non-targeting cas9 phagemid leads to a 2 log lower number of E. coli and S. flexneri CFU when compared to mock infections in vitro and the use of PEG-treated lysates prepared on the mutant pacA lysogen could reduce such non-Cas9-mediated effects on S. flexneri by approximately tenfold. While bacterial cells are actively growing in mock infections, the process of P1 phage infection and/or transduction of the cas9 phagemid could potentially kill and/or reduce the growth rate of bacterial cells. Phage-derived antirestriction proteins, transcription, and the replication of phage DNA are known to trigger various antiphage defense systems, leading to bacterial abortive infection to limit viral infection and replication. Furthermore, given the “headful” DNA packaging mechanism
of P1 that requires ∼100 kbp of DNA substrate for phage maturation, as well as the ability of P1 in packaging DNA substrate without the pac sequence. P1 phagemid transducing particles may be contaminated by bacterial host and/or P1 genomic DNA. Taken together, the presence of P1 antirestriction proteins (i.e., DarA, DarB, and DdrA), cotransduction of host and/or P1 genomic DNA, as well as other aspects of P1 transduction, could potentially contribute toward a lethality effect and/or a lower growth rate of E. coli and S. flexneri. If this is true, the use of transducing particles containing only the phagemid DNA might eliminate the non-Cas9-mediated killing effect on S. flexneri and E. coli. Although the well-studied M13-based phagemid system yields a higher titer of pure transducing particles compared to the P1 phagemid system, M13 adsorption requires the tips of F-pili, which restricts its host range to F+ cells only. This might limit the efficiency of phagemid delivery, especially in targeting clinical isolates of S. flexneri, when compared to P1 phage transduction, which has a broader host range. Tridgett et al., (2021) demonstrated the production of pure cosmid transducing particles, using a mutant P2 lysogen that has its DNA packaging site, cos, replaced with P4 δ and ε gene sequences. However, our previous study indicated a lower transduction efficiency of cosmid DNA into S. flexneri 5a M90T by P2 when compared to P1 infection, despite both phages having broad host ranges. We are currently developing a P4 cosmid system which could produce pure cosmid transducing particles, using the mutant strain of P2 lysogen described by Tridgett et al. Replacing the host range determining region of the P2 tail fiber with that of P1 may improve the transduction efficiency of cosmid DNA into S. flexneri 5a M90T. Comparisons between P1 phagemid lysates and P4 cosmid lysates should provide insights into the effects of using pure cosmid transducing particles on the non-Cas9 killing of S. flexneri.

The versatility of the CRISPR-Cas9 system allows seamless reprogramming of the endonuclease to target conserved chromosomal DNA sequences and/or virulence factors encoded by S. flexneri by modifying its CRISPR guide RNA spacer sequence. Although our results indicate Cas9 killing of S. flexneri with four different chromosomal-targeting guide RNAs, a wider panel of spacer sequences may be useful to identify target sites, improving the Cas9-mediated killing of S. flexneri. Despite a significant cytotoxic effect of P1 transduction on S. flexneri, we demonstrate that P1 transduction of phagemid into both S. flexneri serotypes 2a and 5a highlights the great potential of P1 as a universal S. flexneri targeting strategy, as the targets can be selected to be conserved across S. flexneri serotypes. Furthermore, transduction of phagemid DNA by P1 with its alternative S’ tail fiber is not significantly affected by mutations in the O-antigen modification genes of S. flexneri 2a 2457O and 5a M90T. S. flexneri serotypes, except serotype 6 (S6), share the same O-antigen backbone, therefore P1(S’) could potentially be exploited to transduce phagemid DNA into other serotypes of S. flexneri. We also assessed P1(S’) transduction on serotype 2b, in which preliminary results suggested a higher number of phagemid transductants when compared to P1(S) infection.

In the future, it will be interesting to assess P1 transduction efficiency on the remaining S. flexneri serotypes to determine if the P1 cas9 phagemid can provide broad and efficient targeting of the bacteria.

In summary, combining CRISPR-Cas9 sequence-specific bacterial targeting with P1 bacteriophage-based delivery has great potential to be used as a supplement to conventional antibiotics for the treatment of antibiotic-resistant bacterial infections. As demonstrated in this study, the genetic modification of P1 bacteriophage and the incorporation of the CRISPR-Cas9 system in the form of phagemid are useful for targeting clinically relevant Gram-negative Enterobacteriaceae.

### MATERIALS AND METHODS

**Bacterial and Phage Strains, Plasmids/Phagemids, and Growth Media.** The strains of E. coli and S. flexneri used for this study are listed in Supporting Information Table S1, along with a full description of strain modification (if any) and the purpose of each strain used in this study. Plasmids/phagemids used in this study are listed in Supporting Information Table S2 and were constructed using Gibson assembly. DNA sequences of constructs are listed in Supporting Information Table S3. Bacterial cells were cultured in Luria–Bertani medium (LB) or phage lysis medium (PLM; LB containing 100 mM MgCl₂ and 5 mM CaCl₂), while SM buffer (50 mM Tris–HCl, 8 mM MgSO₄, and 100 mM NaCl, pH 7.5) was used for P1 bacteriophage manipulation, as stated in previous studies of P1 bacteriophage. Concentrations of antibiotics used were 50 μg mL⁻¹ for ampicillin and kanamycin and 25 μg mL⁻¹ for chloramphenicol. All chemical reagents used were analytical grade and purchased from Sigma-Aldrich.

**Bsa1 Cloning of Chromosomal-Targeting Protospacer Sequences.** The CRISPR Cas9 construct used in this study was derived from a pCas9 plasmid (Addgene plasmid #42876), which contains the cas9 gene under a constitutive promoter, a trans-activating CRISPR RNA (tracrRNA) and a CRISPR guide RNA (crRNA). The crRNA sequence contains two Bsa1 sites that allow molecular cloning of a protospacer sequence. 20 bps protospacer sequences targeting the npt and S. flexneri chromosomal sequence(s) with an NGG protospacer adjacent motif (PAM) were designed using the CHOP–CHOP web tool. Primer pairs having a protospacer sequence were designed to have compatible ends for its annealing into the BsaI-digested sites of the crRNA sequence. The design, annealing and cloning of primer pairs into the crRNA sequence were performed as described by Jiang et al., (2013). Restriction digestion of phagemid DNA was carried out using BsaI-HFv2 (NEB), following the manufacturer's protocol. Primer pairs used for protospacer sequence cloning are listed in Supporting Information Table S4.

**Phage Lysate Preparation.** Phage lysates were prepared using a previously established protocol, with some modifications. Briefly, E. coli EMG16 harboring the P1kc lysogen (P1 is used throughout the text instead) were chemically transformed with the J72114-cas9 phagemids using a standard protocol for heat-shocked transformation of E. coli cells. An overnight culture of transformed E. coli P1 lysogen was diluted 1/100 in fresh PLM media and cultured for 1 h at 37 °C. Cell lysis was induced via the addition of L-arabinose (final concentration of 13 mM). Cell lysis was defined as the presence of debris and the clearance of bacterial culture, which happened at approximately 2 h post-induction with 13 mM L-arabinose. Chloroform (final concentration of 2.5%) was added to lysates, and cultures were shaken for 30 min to aid in...
thorough cell lysis and lysate sterilization. Cultures were vortexed, lysates were clarified via centrifugation at maximum speed (16,000g for 3 min), and the supernatant was collected. The supernatant was then passed through a 0.22 μm syringe filter (Millipore) to remove the remaining cell debris. At this stage, the lysates prepared were identified as “crude lysate” and stored at 4 °C.

Our preliminary results suggested that lysates produced from *E. coli* strain NCM3722 harboring P1 contained a higher number of transducing units as compared to that of strain EMG16 (Supporting Information Figure S5). For the preparation of phage lysates using NCM3722 P1, an overnight culture of *E. coli* NCM3722 cells was diluted in fresh LB medium and cultured at 37 °C until an OD_{600} of approximately 1.0. Cells were concentrated tenfold in PLM medium. Crude lysates prepared from *E. coli* EMG16 cells were used to transduce NCM3722 cells (refer to the transduction section of Materials and Methods). Cells were plated onto LB agar with kanamycin and chloramphenicol, which select for both the pac^A::npt P1 and the J72114-pha-geomids, respectively, and plates were incubated at 37 °C for at least 16 h. For lysates prepared from wildtype P1 lysogen, transduced NCM3722 cells were plated onto LB agar with chloramphenicol only. Colonies were picked, and PCR reaction(s) were carried out using primers that anneal specifically to genes of the P1 genome, such as *ipa*. The same protocol for arabinose induction of cell lysis mentioned above was used for making lysates from NCM3722 cells harboring both P1 and the J72114-pha-geomids.

**PEG-6000 Treatment of Phage Lysates.** Treatment of crude lysates with PEG-6000 was carried out based on protocols established in previous studies but with slight modifications. Briefly, the crude lysates prepared were first treated with NaCl to a final concentration of 0.33 M and incubated on ice for 1 h. This step was taken to ensure the precipitation of debris and proteins in the lysates. Lysates were centrifuged at 5000g for 50 min, and the supernatant was collected and further treated with PEG-6000 to a final concentration of 4%, at 4 °C overnight. The use of 4% PEG-6000 was justified by our results, which showed a significant reduction in the amount of wildtype P1 phage and a substantial decrease in the amount of wildtype P1 phage, using previously established protocols. 1.0. Cells were first diluted in fresh LB broth by 1/100 and cultured at 37 °C for at least 16 h before the enumeration of CFU.

**Quantification of Transducing Units/Phagemid.** The transduction assay was carried out based on the protocol established in a previous study with slight modifications. Instead of using a stationary phase culture for transduction, an overnight culture of the indicator *E. coli* strain NCM3722 was first diluted in fresh LB broth by 1/100 and cultured at 37 °C with shaking until an OD_{600} of 0.5. Cells were spun down at 3000g for 5 min and concentrated tenfold in fresh PLM buffer, providing approximately 10^8 cells per 100 μL of bacterial suspension for transduction. An equal volume of diluted (10^1 to 10^5 dilution factor) phage lysate was mixed with the resuspended cells, and phage adsorption was allowed for a maximum of 30 min at 37 °C with shaking. SOC with 10 mM sodium citrate was added to the cell and phage lysate mixture for cell recovery, expression of an antibiotic resistance marker, and quenching of further phage infection via citrate interaction with free calcium ions needed for phage adsorption. SOC recovery was carried out at 37 °C for 1 h with shaking. Serial dilutions of recovered cells were performed and spotted onto plain LB agar as well as LB agar supplemented with 25 μg/mL of chloramphenicol. Agar plates were incubated at 37 °C for at least 16 h before the enumeration of chloramphenicol-resistant colonies. Transducing efficiency would be defined by the percentage of chloramphenicol-resistant colonies against the total CFU recovered on plain LB agar.

**pacA Genetic Modification.** The lambda red recombination technique was used for genetic manipulation of the pacA gene of the P1 genome. The template for recombination was designed to have homology arms complementary to the 3’-end of *ipa* gene and the 5’-end of pac sequence (Supporting Information Tables S3). Synonymous mutations were introduced via codon optimization of the pac site to disrupt the hexamer repeats. A kanamycin resistance cassette was included in the pacA modification template for lambda red recombination as a selection marker for positive clones, which would be integrated into the intergenic region between the *ipa* gene and the *LpPac* promoter. The pacA modification template was first cloned into an empty plasmid with pSC101 as the origin of replication via Gibson assembly, and sequenced and verified. The linear dsDNA substrate used for lambda red recombination was produced via PCR, followed by gel extraction of the PCR product. Lambda red recombineering was carried out based on previously established protocol. Briefly, wildtype *E. coli* EMG16 P1 lysogen was transformed with the pKD46 plasmid. Stationary phase culture of the transformed cells was grown in fresh LB at a dilution factor of 100, at 30 °C with shaking, until an OD_{600} of 0.35. 0.65 M L-arabinose was added to the culture to induce the expression of lambda Red genes (*exo*, *bet*, *gam*) and cultured for a maximum of 30 min at 30 °C, with shaking. Cells were chilled on ice for 40 min and made electrocompetent using standard protocols for preparing electrocompetent cells. 100 ng of dsDNA substrate was electroporated into the cells, followed by growth in SOC at 30 °C with shaking for 2 h. Cells were plated onto LB agar supplemented with 50 μg/mL of kanamycin, and incubated at 37 °C for at least 16 h. Colony PCR was carried out based on previously established protocols. Briefly, a stationary phase culture of naive *E. coli* host strain, NCM3722, was diluted in fresh PLM broth by 1/100 and cultured at 37 °C with shaking until an OD_{600} of 0.5, which took approximately 2.5 h. From our preliminary results, phage lysates prepared from wildtype and pacA^A::npt P1 *E. coli* lysogen would have to be diluted to 10^7 and 10^6, respectively, to give a reasonable amount (50 to 200) of PFU. 1 mL of cell suspension was added to 100 μL of diluted phage lysate,
Following phagemid delivery, larvae were incubated at 32.5 °C. The survival rate was recorded at 24, 48, and 72 h post-infection. Bacterial enumeration from zebrafish was performed at 0 and 6 hpi by mechanical disruption of infected larvae in 0.4% Triton X-100 and plating of serial dilutions onto Congo red-tryptic soy agar plates containing 100 μg/mL carbenicillin.

**Statistical Analysis.** All experiments were carried out with at least three biological and four technical repeats. Calculations of results were performed in Excel (Microsoft, Redmond, WA, USA). GraphPad Prism 6 was used to generate graphs and for statistical analysis. A Shapiro–Wilks normality test was used to determine the distribution of data. To determine statistical significance, Student’s t-test (unequal variance, 2-tailed) or the Kruskal–Wallis test was carried out for the normally distributed and non-normally distributed data sets, respectively. For comparisons involving multiple groups, a Dunn’s multiple comparison test was used to adjust the p-values determined by the Kruskal–Wallis test. For zebrafish experiments, differences in bacterial load were tested using an unpaired t-test on log 10-transformed data (Figure 5a, Supporting Information Figure S3a), while differences in survival were tested using a log-rank (Mantel–Cox) test (Figure 5b, Supporting Information Figure S3b). The statistical test for each of the data sets was listed in the respective figure legend as well as in the main text. Data are expressed as means. p < 0.05 is considered statistically significant. Stars on graphs represent p-values for statistically significant comparisons, with * representing p < 0.05, ** representing p < 0.005, *** representing p < 0.0005, and n.s. representing p > 0.05.

### ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acssynbio.2c00465.

Phagemid construct design; specificity of Cas9 chromosomal-targeting activity; measurement of the non-Cas9-mediated lethality effect of S. flexneri in zebrafish larvae; viability of zebrafish larvae after lyase treatment; comparison of phagemid titers between NCM3722 and EMG16 lysogens; DNA gel verifying the pacA*:npt mutation; relevant genotypes of bacterial strains used; plasmids and phagemids used; primers used; and DNA sequences for all plasmids and phagemids used in this study (PDF)

### AUTHOR INFORMATION

**Corresponding Authors**

Baojun Wang — College of Chemical and Biological Engineering & ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 310058, China; Research Center for Biological Computation, Zhejiang Laboratory, Hangzhou 311000, China; orcid.org/0000-0002-4858-8937; Email: baojun.wang@zju.edu.cn

Serge Mostowy — Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, U.K.; orcid.org/0000-0002-7286-6503; Email: serge.mostowy@lshtm.ac.uk

---

E. coli Targeting Assay. provided a selectable marker for the ensure homogeneity in the bacterial colony. The kanamycin streaking process was repeated for at least three generations to annealing to the junction of integration) of the correct size kanamycin, incubated at 37 °C for at least 16 h; this re-streaking process was repeated for at least three generations to ensure homogeneity in the bacterial colony. The kanamycin resistance cassette was retained in the mutant cell line, which provided a selectable marker for the pacA*:npt P1 lysogen.

**E. coli MC1061::npt and S. flexneri Chromosomal-Targeting Assay.** Stationary phase culture of naïve host cells E. coli MC1061::npt were sub-cultured in fresh PLM at a dilution factor of 100 at 37 °C until an OD<sub>600</sub> of 0.35 is reached. Cells were then diluted to reach an OD<sub>600</sub> of 0.1 in fresh PLM, which gave approximately 1 × 10<sup>8</sup> cells per mL culture. 100 μL of the diluted culture, giving 1 × 10<sup>7</sup> cells, was mixed with an equal volume of phage lysate diluted to the intended MOI. Phage adsorption was allowed for 30 min with shaking at 37 °C. Cells were then recovered, and further phage infection was quenched by the addition of SOC with 10 mM sodium citrate for 1 h at 37 °C with shaking. Serial dilutions of cells were made and spotted onto plain LB agar and/or LB agar with 25 μg/mL of chloramphenicol or 50 μg/mL of kanamycin. To enumerate the input used for the chromosomal-targeting assay, 100 μL of the diluted culture was combined with an equal volume of SM buffer, followed by the addition of SOC with 10 mM sodium citrate, and then plated onto plain LB agar and/or LB agar with 50 μg/mL of kanamycin. Mock-infected cells were treated the same as input cells for phage lysate treatment, but with 100 μL of SM buffer as a negative control. Agar plates were incubated at 37 °C for at least 16 h before enumeration of CFU. The number of recovered CFU was then normalised to that of input cells, except for those plated on LB agar with chloramphenicol, whereby data was normalised to the number of CFU recovered after treatment with phagemids without npt-targeting spacer sequence, since input cells would not have the phagemid hence not chloramphenicol resistant.

**Zebrafish Larvae Model for In Vivo S. flexneri Infection.** Animal experiments were performed according to the Animals (Scientific Procedures) Act 1986 and approved by the Home Office (Project license: P4E664E3C). Protocols are in compliance with standard procedures as reported at zfin.org. Unless specified otherwise, eggs, embryos, and larvae were reared at 28.5 °C in 0.5 × 10<sup>5</sup> medium supplemented with 0.3 μg/mL L-methionine blue. Injections were performed under anesthesia, obtained by supplementing the medium with buffered 200 μg/mL tricaine.

GFP fluorescent and carbenicillin-resistant S. flexneri 5a M90T was prepared for injections as in Torraca et al. 2019. Bacteria were suspended to ∼8000 CFU/mL in PBS containing 2% polyvinylpyrrolidone and 0.5% phenol red. 1 nL of the bacterial suspension was microinjected in the hindbrain ventricle of 2 days post-fertilization (dpf) zebrafish larvae. At 45 min post-infection, infected larvae were injected with a phagmid suspension (3 nL of a phagmid solution in SM Buffer + 5 mM CaCl<sub>2</sub> corresponding to ∼10<sup>8</sup> P1 transducing units).
Authors
Yang W. Huan — School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3PF, U.K.
Vincenzo Torraca — Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, U.K.; School of Life Sciences, University of Westminster, London W1B 2HW, U.K.; orcid.org/0000-0001-7340-0249
Russell Brown — School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3PF, U.K.
Jidapha Fa-arun — School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3PF, U.K.
Sydney L. Miles — Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, U.K.
Diego A. Oyarzún — School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3PF, U.K.; School of Informatics, University of Edinburgh, Edinburgh EH8 9AB, U.K.; orcid.org/0000-0002-0381-5278

Complete contact information is available at: https://pubs.acs.org/10.1021/acssynbio.2c00465

Author Contributions
B.W. conceived and supervised the study. B.W., Y.H., V.T., R.B., and S.M. designed the experiments. Y.H. and R.B. performed the experiments related to the P1 phagemid design, construction, production, and characterization in bacterial culture and P1 phage genome engineering. V.T. and S.L.M. performed zebrafish infection experiments. Y.H., V.T., R.B., and S.M. designed the experiments. Y.H. and R.B. contributed equally.

Notes
The authors declare no competing financial interest. All data in the main text and the Supporting Information are available from the corresponding author upon reasonable request.

ACKNOWLEDGMENTS
This work was supported by the Bill and Melinda Gates Foundation under the Grand Challenges Explorations grant (OPP1139488) and the UK Research and Innovation Future Leaders Fellowship [MR/S018875/1]. B.W. is supported by the Fundamental Research Funds for the Central Universities (226-2022-00178 and 226-2022-00214), the Natural Science Foundation of China (32271475), and the Kumpeng Action Program Award of Zhejiang Province. J.F. was supported by the Darwin Trust Scholarship of Edinburgh. V.T. is supported by an LSHTM/Wellcome Trust Institutional Strategic Support Fund (ISSF) Fellowship (204928/Z/16/Z). S.L.M. is supported by a Biotechnology and Biological Sciences Research Council LiDo Ph.D. studentship (BB/T008709/1). Work in the S.M. laboratory is supported by a European Research Council Consolidator Grant (grant agreement no. 772853-ENTRAGMENT), a Wellcome Trust Senior Research Fellowship (206444/Z/17/Z), and the Lister Institute of Preventive Medicine.

REFERENCES


